Thus, the catastrophic Patient 2 symptoms are not due to any unique dFmr1 I304N effects, but are rather presumably attributable to the combined FXS and GSD-IX disease states, with the joint loss of both FMRP and PHKA2 functions within the same patient. The gene discussed is PHKA2; the disease is fragile X syndrome.